CDKN2A and glioblastoma: Since the p53 pathway (including CDKN2A, MDM2, and TP53) is deregulated in ~85% of tumors [63], this p53-independent cytotoxicity from the co-treatment of T + N + P is very encouraging for GBM treatment.